Ocular Therapeutix (OCUL) vs Syndax Pharmaceuticals (SNDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Syndax Pharmaceuticals (SNDX) has outperformed Ocular Therapeutix (OCUL) over the past year, gaining 3.5% versus a loss of 37.2%. Over five years, SNDX leads with a -8.4% price change compared with -35.4% for OCUL. Ocular Therapeutix is the larger company by market cap ($1.62 billion vs $1.52 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | OCUL | SNDX |
|---|---|---|
| Share price | $7.38 | $17.04 |
| Market cap | $1.62B | $1.52B |
| 1-day change | +2.01% | +0.04% |
| YTD return | -40.44% | -18.94% |
| 1-year return | -37.24% | +3.53% |
| 5-year return | -35.39% | -8.39% |
| EPS (TTM) | $-1.40 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.44 | $25.59 |
| 52-week low | $6.23 | $12.99 |
| Distance from 52-week high | -55.14% | -33.42% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +267.32% | +120.40% |
| Average volume | 2.78M | 1.54M |
| Shares outstanding | 219.62M | 89.30M |
| Employees | 325 | 298 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SNDX has outperformed OCUL by 40.8 percentage points over the past year.
About Ocular Therapeutix
OCUL stock →Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
OCUL vs SNDX FAQ
Which is bigger, Ocular Therapeutix or Syndax Pharmaceuticals?
Ocular Therapeutix (OCUL) is larger, with a market capitalization of $1.62B compared with $1.52B for Syndax Pharmaceuticals (SNDX).
Which stock has performed better over the past year, OCUL or SNDX?
SNDX returned +3.53% over the past 12 months, compared with -37.24% for OCUL (price return, excluding dividends). Past performance does not predict future results.
Are Ocular Therapeutix and Syndax Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.